Backgrounds & Aims: Strains belonging to bifidobacteria have been documented as being helpful in adults with intestinal dysbiosis conditions, like those related to irritable bowel syndrome (IBS). This review aims to present the most relevant evidence regarding the efficacy of Bifidobacterium longum W11, a Bifidobacterium used in clinical settings for conditions such as IBS and inflammatory bowel disease.

Methods: The following electronic databases were systematically searched up to August 2020: MEDLINE (via PubMed), EMBASE, Cochrane Central Database of Controlled Trials (via CENTRAL), Google Scholar, and Clinicaltrials.gov.

Results: Data arising from pooled analysis, 7 in vitro/pharmacological studies, 7 clinical trials including 1 randomized, double-blind and placebo-controlled, showed that the probiotic strain B. longum W11 has been extensively studied for its efficacy in subjects with IBS with constipation, leading to a significant reduction in symptoms. In particular, its role in alleviating constipation was also confirmed in subjects for whom a low-calorie weight-loss diet led to the slowing down of gut motility. The probiotic characteristics of B. longum W11 were further demonstrated in the treatment of minimal hepatic encephalopathy and hepatic disease. The most remarkable trait of B. longum W11 is its non-transmissible antibiotic resistance, due to a nucleotide polymorphism mutation in the rpoB gene, making it resistant to antibiotics of the rifampicin group, including rifaximin. The co-administration of B. longum W11 and rifaximin in patients with symptomatic uncomplicated diverticular disease brought about a further significant improvement in the clinical condition compared to patients treated with rifaximin alone. B. longum W11 is a probiotic which could synergize with rifaximin as an adjuvant to antibiotic treatment.

Conclusions: Taken altogether these findings demonstrate the clinical role of the strain W11 both in some functional and in some inflammatory bowel diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clnesp.2020.12.025DOI Listing

Publication Analysis

Top Keywords

longum w11
24
bifidobacterium longum
8
w11
8
inflammatory bowel
8
clinical
5
rifaximin
5
longum
5
w11 uniqueness
4
uniqueness individual
4
individual combined
4

Similar Publications

Recent investigations have highlighted, both experimentally and clinically, that probiotic strains equipped with arabinofuranosidase, in particular and , favor regular intestinal motility, thus counteracting constipation. By analyzing the gene expression and the proliferative response in the presence of arabinan of the probiotic W11, a strain previously validated as an anti-constipation probiotic, we have speculated that its response mechanism to arabinan can effectively explain its clinical action. Our approach could be used in the future to select probiotics endowed with arabinofuranosidase-related anti-constipation effects.

View Article and Find Full Text PDF

Backgrounds & Aims: Strains belonging to bifidobacteria have been documented as being helpful in adults with intestinal dysbiosis conditions, like those related to irritable bowel syndrome (IBS). This review aims to present the most relevant evidence regarding the efficacy of Bifidobacterium longum W11, a Bifidobacterium used in clinical settings for conditions such as IBS and inflammatory bowel disease.

Methods: The following electronic databases were systematically searched up to August 2020: MEDLINE (via PubMed), EMBASE, Cochrane Central Database of Controlled Trials (via CENTRAL), Google Scholar, and Clinicaltrials.

View Article and Find Full Text PDF

Background: In medical practice, the use of rifaximin and a probiotic is quite common in patients with a diagnosis of symptomatic uncomplicated diverticular disease (SUDD), with the latter being administered at the end of the rifaximin cycle. The opportunity of having a probiotic strain (Bifidobacterium longum W11) described as being resistant to rifaximin has prompted us to use it routinely in subjects with SUDD, administering it concomitantly with rifaximin.

Methods: Retrospectively, we have analyzed whether our approach conferred a real clinical advantage to patients.

View Article and Find Full Text PDF

Immunomodulatory Effects of Bifidobacterium longum W11 Produced Exopolysaccharide on Cytokine Production.

Curr Pharm Biotechnol

June 2018

Department of Biomedical and Biotechnological Sciences, Section of Microbiology, University of Catania, Via Santa Sofia 97, 95123 Catania (CT), Italy.

Background: Health benefits, including immune modulating capability, exerted by Bifidobacterium strains have been attributed to their exopolysaccharides (EPSs).

Objective: The effects of the purified EPS from B. longum W11 on cytokine production by peripheral blood mononuclear cells (PBMCs) alone or ConA-stimulated were investigated.

View Article and Find Full Text PDF

Chemical and biological properties of the novel exopolysaccharide produced by a probiotic strain of Bifidobacterium longum.

Carbohydr Polym

October 2017

Instituto de Productos Lácteos de Asturias-Consejo Superior de Investigaciones Científicas (IPLA-CSIC), Paseo Río Linares s/n 33300 Villaviciosa, Asturias, Spain. Electronic address:

Bifidobacterium longum W11 is a commercialized probiotic that has an exopolysaccharide (EPS) layer covering its surface which could play a role in the beneficial properties attributed to the strain; thus, we have carried out chemical and biological analyses of this polymer. The eps cluster putatively involved in the polymer synthesis presented a unique structural organization not previously reported in bifidobacteria. B.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!